Astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook
Open the sourceReported by Seeking Alpha, seekingalpha.com, 4 November 2026
65Impact 65 of 100, notable
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.
Named in this story
Astellas Pharma